Molecular diagnostic trends in urological cancer: Biomarkers for non-invasive diagnosis

V. Urquidi, C. J. Rosser, Steven Goodison

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

The early detection of urological cancers is pivotal for successful patient treatment and management. The development of molecular assays that can diagnose disease accurately, or that can augment current methods of evaluation, would be a significant advance. Ideally, such molecular assays would be applicable to non-invasively obtained body fluids, enabling not only diagnosis of at risk patients, but also asymptomatic screening, monitoring disease recurrence and response to treatment. The advent of advanced proteomics and genomics technologies and associated bioinformatics development is bringing these goals into focus. In this article we will discuss the promise of biomarkers in urinalysis for the detection and clinical evaluation of the major urological cancers, including bladder, kidney and prostate. The development of urine-based tests to detect urological cancers would be of tremendous benefit to both patients and the healthcare system.

Original languageEnglish (US)
Pages (from-to)3653-3663
Number of pages11
JournalCurrent Medicinal Chemistry
Volume19
Issue number22
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Urologic Neoplasms
Molecular Pathology
Tumor Biomarkers
Assays
Patient treatment
Body fluids
Biomarkers
Bioinformatics
Screening
Urinalysis
Body Fluids
Genomics
Computational Biology
Early Detection of Cancer
Urinary Bladder Neoplasms
Proteomics
Monitoring
Prostatic Neoplasms
Urine
Technology

Keywords

  • Biomarkers
  • Body fluids
  • Diagnosis
  • Non-invasive
  • Urinary
  • Urological cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Molecular diagnostic trends in urological cancer : Biomarkers for non-invasive diagnosis. / Urquidi, V.; Rosser, C. J.; Goodison, Steven.

In: Current Medicinal Chemistry, Vol. 19, No. 22, 01.08.2012, p. 3653-3663.

Research output: Contribution to journalReview article

@article{f4d84956b31c47679fc45e4085c8fa1b,
title = "Molecular diagnostic trends in urological cancer: Biomarkers for non-invasive diagnosis",
abstract = "The early detection of urological cancers is pivotal for successful patient treatment and management. The development of molecular assays that can diagnose disease accurately, or that can augment current methods of evaluation, would be a significant advance. Ideally, such molecular assays would be applicable to non-invasively obtained body fluids, enabling not only diagnosis of at risk patients, but also asymptomatic screening, monitoring disease recurrence and response to treatment. The advent of advanced proteomics and genomics technologies and associated bioinformatics development is bringing these goals into focus. In this article we will discuss the promise of biomarkers in urinalysis for the detection and clinical evaluation of the major urological cancers, including bladder, kidney and prostate. The development of urine-based tests to detect urological cancers would be of tremendous benefit to both patients and the healthcare system.",
keywords = "Biomarkers, Body fluids, Diagnosis, Non-invasive, Urinary, Urological cancer",
author = "V. Urquidi and Rosser, {C. J.} and Steven Goodison",
year = "2012",
month = "8",
day = "1",
doi = "10.2174/092986712801661103",
language = "English (US)",
volume = "19",
pages = "3653--3663",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "22",

}

TY - JOUR

T1 - Molecular diagnostic trends in urological cancer

T2 - Biomarkers for non-invasive diagnosis

AU - Urquidi, V.

AU - Rosser, C. J.

AU - Goodison, Steven

PY - 2012/8/1

Y1 - 2012/8/1

N2 - The early detection of urological cancers is pivotal for successful patient treatment and management. The development of molecular assays that can diagnose disease accurately, or that can augment current methods of evaluation, would be a significant advance. Ideally, such molecular assays would be applicable to non-invasively obtained body fluids, enabling not only diagnosis of at risk patients, but also asymptomatic screening, monitoring disease recurrence and response to treatment. The advent of advanced proteomics and genomics technologies and associated bioinformatics development is bringing these goals into focus. In this article we will discuss the promise of biomarkers in urinalysis for the detection and clinical evaluation of the major urological cancers, including bladder, kidney and prostate. The development of urine-based tests to detect urological cancers would be of tremendous benefit to both patients and the healthcare system.

AB - The early detection of urological cancers is pivotal for successful patient treatment and management. The development of molecular assays that can diagnose disease accurately, or that can augment current methods of evaluation, would be a significant advance. Ideally, such molecular assays would be applicable to non-invasively obtained body fluids, enabling not only diagnosis of at risk patients, but also asymptomatic screening, monitoring disease recurrence and response to treatment. The advent of advanced proteomics and genomics technologies and associated bioinformatics development is bringing these goals into focus. In this article we will discuss the promise of biomarkers in urinalysis for the detection and clinical evaluation of the major urological cancers, including bladder, kidney and prostate. The development of urine-based tests to detect urological cancers would be of tremendous benefit to both patients and the healthcare system.

KW - Biomarkers

KW - Body fluids

KW - Diagnosis

KW - Non-invasive

KW - Urinary

KW - Urological cancer

UR - http://www.scopus.com/inward/record.url?scp=84865206873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865206873&partnerID=8YFLogxK

U2 - 10.2174/092986712801661103

DO - 10.2174/092986712801661103

M3 - Review article

C2 - 22680923

AN - SCOPUS:84865206873

VL - 19

SP - 3653

EP - 3663

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 22

ER -